Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

RP 59500

Known as: RP-59500 
 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

dalfopristin / quinupristin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
1998
Highly Cited
1998
Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada.
A total of 200 medical center laboratories in the USA and Canada contributed results of testing quinupristin-dalfopristin, a… Expand
Highly Cited
1995
Highly Cited
1995
Treatment of experimental endocarditis due to erythromycin-susceptible or -resistant methicillin-resistant Staphylococcus aureus with RP 59500.
RP 59500 is a new injectable streptogramin composed of two synergistic components (quinupristin and dalfopristin) which are… Expand
Highly Cited
1995
Highly Cited
1995
Critical influence of resistance to streptogramin B-type antibiotics on activity of RP 59500 (quinupristin-dalfopristin) in experimental endocarditis due to Staphylococcus aureus.
In order to determine the microbiological and pharmacokinetic parameters that best predicted the in vivo antistaphylococcal… Expand
1995
1995
In vitro activity of RP 59500 (quinupristin/dalfopristin) against antibiotic-resistant strains of Streptococcus pneumoniae and enterococci.
The activity of RP 59500 (quinupristin/dalfopristin) was evaluated in vitro against antibiotic-resistant strains of Streptococcus… Expand
Highly Cited
1994
Highly Cited
1994
Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology.
Time-kill studies were used to examine the in vitro activities of penicillin G, RP 59500, erythromycin, ciprofloxacin… Expand
  • table 1
  • figure 2
  • figure 3
  • table 2
Highly Cited
1992
Highly Cited
1992
RP 59500: a proposed mechanism for its bactericidal activity.
RP 59500 is a combination of RP 57669 and RP 54476, which are semisynthetic water soluble derivatives of pristinamycin IA (PIA… Expand
Highly Cited
1992
Highly Cited
1992
Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and…
The MICs of four new quinolones, sparfloxacin (AT-4140, CI-978), PD 131628 (the active form of the prodrug CI-990), temafloxacin… Expand
  • table 1
1992
1992
Post-antibiotic effects of RP 59500 with Staphylococcus aureus.
The post-antibiotic effect (PAE) of the semisynthetic streptogramin RP 59500 was evaluated with four clinical isolates of… Expand
Highly Cited
1992
Highly Cited
1992
Activity of RP 59500, a new parenteral semisynthetic streptogramin, against staphylococci with various mechanisms of resistance to macrolide-lincosamide-streptogramin antibiotics.
RP 59500 is a semisynthetic streptogramin (Sg) composed of two synergic components: RP 57669 and RP 54476. The activities of RP… Expand
Highly Cited
1992
Highly Cited
1992
The in-vitro activity of new streptogramins, RP 59500, RP 57669 and RP 54476, alone and in combination.
RP 59500 is a 30:70 mixture of RP 57669 and RP 54476. The activity of RP 59500 and its two components against Gram-positive and… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE